Published in Science on April 20, 1990
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol (1994) 3.45
Expression of virus-encoded proteinases: functional and structural similarities with cellular enzymes. Microbiol Rev (1993) 3.33
Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol (1995) 3.05
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A (1994) 3.00
Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol (1993) 2.96
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother (1997) 2.57
N-Terminal extension of human immunodeficiency virus capsid protein converts the in vitro assembly phenotype from tubular to spherical particles. J Virol (1998) 2.49
An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci U S A (1990) 2.32
Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein. J Virol (1991) 2.23
Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother (1995) 2.21
In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci U S A (1993) 2.16
Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J Virol (1995) 2.05
Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J Virol (1995) 1.97
Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci U S A (1996) 1.93
Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother (1998) 1.92
Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase. J Clin Invest (1991) 1.91
Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci U S A (1992) 1.89
Active foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein. J Virol (1995) 1.81
Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J Virol (1994) 1.80
Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob Agents Chemother (2006) 1.72
Actin associates with the nucleocapsid domain of the human immunodeficiency virus Gag polyprotein. J Virol (1999) 1.59
Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev (1995) 1.49
Target repurposing for neglected diseases. Future Med Chem (2011) 1.48
Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother (1998) 1.46
Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother (2002) 1.45
Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous, single-chain tethered dimer. Proc Natl Acad Sci U S A (1990) 1.40
Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J Virol (2010) 1.39
HIV-1 Protease: Structural Perspectives on Drug Resistance. Viruses (2009) 1.37
X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. Proc Natl Acad Sci U S A (1990) 1.34
In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob Agents Chemother (1993) 1.33
High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1. J Virol (2000) 1.29
BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother (2000) 1.26
Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. Antimicrob Agents Chemother (1992) 1.24
Copper inhibits the protease from human immunodeficiency virus 1 by both cysteine-dependent and cysteine-independent mechanisms. Proc Natl Acad Sci U S A (1991) 1.24
Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins. J Med Chem (2009) 1.23
Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation. J Virol (1992) 1.21
Molecular Basis for Drug Resistance in HIV-1 Protease. Viruses (2010) 1.20
Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex. Proc Natl Acad Sci U S A (1990) 1.19
Importance of protease cleavage sites within and flanking human immunodeficiency virus type 1 transframe protein p6* for spatiotemporal regulation of protease activation. J Virol (2008) 1.14
Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS (2008) 1.12
Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol (1998) 1.12
Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm (2007) 1.10
Design of potent and selective human cathepsin K inhibitors that span the active site. Proc Natl Acad Sci U S A (1997) 1.10
Current and Novel Inhibitors of HIV Protease. Viruses (2009) 1.10
The eukaryotic translation initiation factor 4GI is cleaved by different retroviral proteases. J Virol (2003) 1.06
beta-Galactosidase containing a human immunodeficiency virus protease cleavage site is cleaved and inactivated by human immunodeficiency virus protease. Proc Natl Acad Sci U S A (1990) 1.06
Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase. J Virol (1994) 1.06
Plasma membrane targeting of chimeric intracisternal A-type particle polyproteins leads to particle release and specific activation of the viral proteinase. J Virol (1997) 1.05
Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease. J Med Chem (2009) 1.05
Current perspectives on HIV-1 antiretroviral drug resistance. Viruses (2014) 1.04
Structure-based discovery of antibacterial drugs. Nat Rev Microbiol (2010) 1.04
The late-domain-containing protein p6 is the predominant phosphoprotein of human immunodeficiency virus type 1 particles. J Virol (2002) 1.04
Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob Agents Chemother (1996) 1.03
Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production. J Virol (2002) 1.03
Bile pigments as HIV-1 protease inhibitors and their effects on HIV-1 viral maturation and infectivity in vitro. Biochem J (1996) 1.02
Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1997) 1.00
In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor. Antimicrob Agents Chemother (1993) 1.00
Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles. J Virol (1991) 1.00
An engineered retroviral proteinase from myeloblastosis associated virus acquires pH dependence and substrate specificity of the HIV-1 proteinase. EMBO J (1992) 0.98
Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease. Antimicrob Agents Chemother (1995) 0.98
Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob Agents Chemother (1996) 0.98
Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob Agents Chemother (1997) 0.97
Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. PLoS One (2010) 0.97
Insights into saquinavir resistance in the G48V HIV-1 protease: quantum calculations and molecular dynamic simulations. Biophys J (2004) 0.97
Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. J Med Chem (2007) 0.97
Antiviral therapy: current concepts and practices. Clin Microbiol Rev (1992) 0.96
Constitutive production of nonenveloped human immunodeficiency virus type 1 particles by a mammalian cell line and effects of a protease inhibitor on particle maturation. Antimicrob Agents Chemother (1994) 0.96
Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335. Antimicrob Agents Chemother (1992) 0.96
Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. J Virol (1997) 0.94
Isolation of peptide aptamers that inhibit intracellular processes. Proc Natl Acad Sci U S A (2000) 0.93
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin. Proteins (2009) 0.92
Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: rethinking the "fireman's grip" hypothesis. Protein Sci (2000) 0.92
Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases. J Virol (2001) 0.91
Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation. Antimicrob Agents Chemother (2004) 0.91
Potency and selectivity of inhibition of human immunodeficiency virus protease by a small nonpeptide cyclic urea, DMP 323. Antimicrob Agents Chemother (1994) 0.89
Insights from atomic-resolution X-ray structures of chemically synthesized HIV-1 protease in complex with inhibitors. J Mol Biol (2007) 0.88
Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention. Antimicrob Agents Chemother (2012) 0.88
Effects of U-75875, a peptidomimetic inhibitor of retroviral proteases, on simian immunodeficiency virus infection in rhesus monkeys. Antimicrob Agents Chemother (1994) 0.88
Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J Virol (2000) 0.88
Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev (2016) 0.88
Substrate requirements of hepatitis C virus serine proteinase for intermolecular polypeptide cleavage in Escherichia coli. J Virol (1994) 0.87
Solvent accessibility as a predictive tool for the free energy of inhibitor binding to the HIV-1 protease. Protein Sci (1995) 0.87
Sparse Representation for Prediction of HIV-1 Protease Drug Resistance. Proc SIAM Int Conf Data Min (2013) 0.86
Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition. Antimicrob Agents Chemother (1992) 0.85
Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies. Org Biomol Chem (2008) 0.85
Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects. AIDS Res Ther (2006) 0.84
DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein. Antimicrob Agents Chemother (1994) 0.84
CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. Antimicrob Agents Chemother (1993) 0.84
Antiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in tissue culture. Antimicrob Agents Chemother (1993) 0.84
Synergistic binding of inhibitors to the protease from HIV type 1. Biochem J (1996) 0.84
A target repurposing approach identifies N-myristoyltransferase as a new candidate drug target in filarial nematodes. PLoS Negl Trop Dis (2014) 0.84
Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif. Proc Natl Acad Sci U S A (1998) 0.83
Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors. Antimicrob Agents Chemother (2000) 0.83
Novel bacteriological assay for detection of potential antiviral agents. Antimicrob Agents Chemother (1990) 0.83
Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag. J Virol (2001) 0.83
The changing pattern of prenatal care utilization in the United States, 1981-1995, using different prenatal care indices. JAMA (1998) 4.56
Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev (2008) 3.46
The fate of integrated treatment: whatever happened to the biopsychosocial psychiatrist? Am J Psychiatry (2001) 3.41
An economic appraisal of alternative pre-natal screening programmes for Down's syndrome. J Public Health Med (1993) 2.92
Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex. J Exp Med (1989) 2.69
Combined biochemical and serological typing of clinical isolates of Klebsiella. Appl Microbiol (1974) 2.55
In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis (1996) 2.34
Safety and activity of saquinavir in HIV infection. Lancet (1995) 2.32
Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology (1995) 2.29
Short compared with standard duration of antibiotic treatment for urinary tract infection: a systematic review of randomised controlled trials. Arch Dis Child (2002) 2.28
Activation of Raf-1 by 14-3-3 proteins. Nature (1994) 2.22
Annual summary of vital statistics--1996. Pediatrics (1997) 2.21
Analogues of beta-LPH61-64 possessing selective agonist activity at mu-opiate receptors. Eur J Pharmacol (1981) 2.14
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev (2006) 2.13
Preliminary physiological characterization of temperature-sensitive mutants of vesicular stomatitis virus. J Virol (1971) 2.11
The development of a tool to assess neonatal pain. Neonatal Netw (1993) 2.08
Annual summary of vital statistics--1998. Pediatrics (1999) 2.01
Antibiotics and surgery for vesicoureteric reflux: a meta-analysis of randomised controlled trials. Arch Dis Child (2003) 1.99
Isolation and characterization of temperature-sensitive mutants of vesicular stomatitis virus, New Jersey serotype. J Virol (1971) 1.97
Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res (1991) 1.96
Emergence of gentamicin-resistant Klebsiella in a general hospital. Antimicrob Agents Chemother (1977) 1.96
Epidemiology of headache and childhood migraine in an urban general practice using Ad Hoc, Vahlquist and IHS criteria. Dev Med Child Neurol (1992) 1.94
Problems of diagnosis of hearing loss in the young child. Proc R Soc Med (1971) 1.93
Births: final data for 1999. Natl Vital Stat Rep (2001) 1.93
Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol (2001) 1.90
Annual summary of vital statistics--1995. Pediatrics (1996) 1.86
Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect (2007) 1.84
Recruitment of CREB binding protein is sufficient for CREB-mediated gene activation. Mol Cell Biol (2000) 1.78
The control of imitative and nonimitative behaviors in severely retarded children through "generalized-instruction following". J Exp Child Psychol (1971) 1.74
Childhood deafness in the European community. Scand Audiol (1981) 1.73
Library weeds. Bull Med Libr Assoc (1971) 1.73
Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children. Cochrane Database Syst Rev (2003) 1.72
Teaching of formal courses by medical librarians. J Med Educ (1975) 1.67
Complications associated with a narrow bore nasogastric tube. Ann Otol Rhinol Laryngol (1984) 1.62
Traumatic deidealization and the future of medicine. JAMA (1990) 1.61
What happens to medical library interns? Bull Med Libr Assoc (1967) 1.60
Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev (2005) 1.60
The course of alcohol withdrawal in a general hospital. QJM (1997) 1.59
Daytime urinary incontinence in primary school children: a population-based survey. J Pediatr (2000) 1.58
The human EGF receptor gene: structure of the 110 kb locus and identification of sequences regulating its transcription. Oncogene Res (1988) 1.58
Susceptibility of 1,500 isolates of Pseudomonas aeruginosa to gentamicin, carbenicillin, colistin, and polymyxin B. Antimicrob Agents Chemother (1974) 1.54
The Kidney Disease: improving Global Outcomes website: comparison of guidelines as a tool for harmonization. Kidney Int (2007) 1.53
Zymogens of proteolytic enzymes. Science (1973) 1.51
Renal impairment and anaemia in a population-based study of older people. Intern Med J (2004) 1.51
Births and deaths: preliminary data for 1998. Natl Vital Stat Rep (1999) 1.51
Hemorrhagic shock and encephalopathy: clinical, pathologic, and biochemical features. J Pediatr (1989) 1.50
Treatment for peritoneal dialysis-associated peritonitis. Cochrane Database Syst Rev (2008) 1.48
Growth hormone treatment in children with chronic renal failure: a meta-analysis of randomized controlled trials. J Pediatr (2001) 1.48
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev (2008) 1.47
Glue ear guidelines. Lancet (1993) 1.47
Trends in twin birth outcomes and prenatal care utilization in the United States, 1981-1997. JAMA (2000) 1.43
Texture perception through direct and indirect touch: an analysis of perceptual space for tactile textures in two modes of exploration. Somatosens Mot Res (2007) 1.43
A prospective survey of reactions to blood tests by children and adolescents. Pain (1990) 1.42
Trends in twin and triplet births: 1980-97. Natl Vital Stat Rep (1999) 1.42
O serotyping of Providencia stuartii isolates collected from twelve hospitals. J Clin Microbiol (1979) 1.40
Staff evaluation of supervisors. Spec Libr (1979) 1.40
Expression of type VI collagen in uveal melanoma: its role in pattern formation and tumor progression. Lab Invest (1996) 1.40
Isolation and characterization of beta-glucan receptors on human mononuclear phagocytes. J Exp Med (1991) 1.40
Auditory perception. Br Med J (1973) 1.39
Stereochemistry of 1-(4'-hydroxyphenyl)ethanol produced by hydroxylation of 4-ethylphenol by p-cresol methylhydroxylase. Biochem J (1984) 1.38
Preparation and Use of Dried Plasma for Transfusion. Br Med J (1940) 1.38
Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant (2007) 1.37
The autoactivation of trypsinogen. J Biol Chem (1971) 1.35
Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev (2007) 1.34
Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic- or -aromatic*pro- cleavage sites. Biochemistry (1992) 1.33
Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev (2008) 1.32
Differences in duration of pregnancy. Negro and white women of low socioeconomic class. Arch Environ Health (1967) 1.32
Births and deaths: United States, 1996. Mon Vital Stat Rep (1997) 1.32
Do we now have the tools to assess operative skill? ANZ J Surg (2002) 1.32
A comparative study of 63 strains of ECHO virus type 30. Arch Gesamte Virusforsch (1968) 1.32
Births: final data for 1997. Natl Vital Stat Rep (1999) 1.30
Births: final data for 1998. Natl Vital Stat Rep (2000) 1.29
A systematic series of synthetic chromophoric substrates for aspartic proteinases. Biochem J (1986) 1.28
Computerised decision support systems in order communication for diagnostic, screening or monitoring test ordering: systematic reviews of the effects and cost-effectiveness of systems. Health Technol Assess (2010) 1.26
Metabolic fate of extracted glucose in normal human myocardium. J Clin Invest (1985) 1.26
Mechanical impact induces cartilage degradation via mitogen activated protein kinases. Osteoarthritis Cartilage (2010) 1.25
Antigen processing for presentation by class II major histocompatibility complex requires cleavage by cathepsin E. Eur J Immunol (1992) 1.25
High level expression and characterisation of Plasmepsin II, an aspartic proteinase from Plasmodium falciparum. FEBS Lett (1994) 1.23
Immunolocalization of cathepsin D in normal and neoplastic human tissues. J Clin Pathol (1986) 1.22
The activity of candidate virucidal agents, low pH and genital secretions against HIV-1 in vitro. Int J STD AIDS (1995) 1.22
The activation of bovine pepsinogen. Sequence of the peptides released, identification of a pepsin inhibitor. J Biol Chem (1974) 1.21
Changes in HIV-related behaviors among heterosexual alcoholics following addiction treatment. Drug Alcohol Depend (1997) 1.21
D-Arg[Hyp3-Thi5-D-Tic7-Tic8]-bradykinin, a potent antagonist of smooth muscle BK2 receptors and BK3 receptors. Br J Pharmacol (1991) 1.20
Smooth muscle actin expression during P19 embryonal carcinoma differentiation in cell culture. J Cell Physiol (1990) 1.20
Subsite preferences of retroviral proteinases. Methods Enzymol (1994) 1.19
Expression and characterisation of plasmepsin I from Plasmodium falciparum. Eur J Biochem (1997) 1.19
Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev (2006) 1.19
Prognostic factors in choroidal and ciliary body melanomas with extrascleral extension. Am J Ophthalmol (1986) 1.17
Corticosteroid therapy in nephrotic syndrome: a meta-analysis of randomised controlled trials. Arch Dis Child (2000) 1.17
Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases. FEBS Lett (1989) 1.16
Malignant melanoma of the nasal cavity in Ugandan Africans. Relationship of ectopic pigmentation. Cancer (1967) 1.16
Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev (2005) 1.14
HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS (1998) 1.13
Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast. Virchows Arch A Pathol Anat Histopathol (1993) 1.13
Medical library internship at NIH. Bull Med Libr Assoc (1967) 1.13
Secondary structure of a herpes simplex virus glycoprotein D antigenic domain. Int J Pept Protein Res (1986) 1.12
Childhood depression and risk of suicide: a preliminary report of a longitudinal study. J Am Acad Child Adolesc Psychiatry (1993) 1.12
Comparison of bacteriophage typing, serotyping, and biotyping as aids in epidemiological surveillance of Klebsiella infections. J Clin Microbiol (1978) 1.12